Patents Examined by Brad Duffy
  • Patent number: 11332539
    Abstract: Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: May 17, 2022
    Assignee: Thomas Jefferson University
    Inventor: Mark L. Tykocinski
  • Patent number: 11331394
    Abstract: This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: May 17, 2022
    Assignee: SEAGEN INC.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • Patent number: 11319371
    Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 3, 2022
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Christian Hess, Sebastian Meyer, Alexandre Simonin, Teddy Beltrametti, David Urech
  • Patent number: 11305011
    Abstract: The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: April 19, 2022
    Assignee: HAEMALOGIX PTY. LTD.
    Inventors: Kenneth Micklethwaite, Rosanne Dunn, David Gottlieb, Grant Logan
  • Patent number: 11287428
    Abstract: The present disclosure relates to a method for diagnosing in a subject the progression from myelodysplastic syndrome (MDS) to acute myelogenous leukemia (AML). Also disclosed are methods of treating AML in a subject diagnosed by the disclosed methods.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: March 29, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Alan List, Sheng Wei
  • Patent number: 11279769
    Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express the glycoepitope STn on TAG-72.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: March 22, 2022
    Assignee: Helixmith Co., Ltd
    Inventors: Richard Morgan, Kevin Friedman, Seung Shin Yu, Jae-Gyun Jeong, Jin-A Chae
  • Patent number: 11274153
    Abstract: Disclosed is a nanobody against the human programmed death factor PD-LI. The antibody has the function of blocking the binding of PD-LI to the receptor PD-I. Disclosed are the nanobody and the gene sequence encoding the nanobody, the corresponding expression vector and the host cell capable of expressing the nanobody, and the method for producing the nanobody. At the same time, also disclosed is the sequence of the humanized PD-LI nanobody. The humanized nanobody still has the function of blocking the binding of PD-LI to PD-1, and has a relatively high affinity and a relatively good specificity.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: March 15, 2022
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Xiaoning Shen, Xiaoniu Miao, Xiaolin Liu
  • Patent number: 11267904
    Abstract: Disclosed is a method for controlling affinity of an antibody for an antigen, comprising substituting at least 3 amino acid residues of framework region 3 (FR3) defined by the Chothia method with charged amino acid residues, in an antibody whose electrical characteristic of complementarity determining region (CDR) based on the amino acid sequence of the CDR is neutral or negatively charged.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: March 8, 2022
    Assignee: SYSMEX CORPORATION
    Inventors: Shingo Maeta, Atsushi Fukunaga
  • Patent number: 11266739
    Abstract: Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and/or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and/or administering the cells expressing the second receptor to a subject having received the first administration.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: March 8, 2022
    Assignee: Juno Therapeutics, Inc.
    Inventor: Mark J. Gilbert
  • Patent number: 11267875
    Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 8, 2022
    Assignee: Yale University
    Inventors: Dianqing Wu, Bo Chen, Hai Wu
  • Patent number: 11261226
    Abstract: The present disclosure is directed, in some embodiments, to methods and compositions of comprising a cell having a non-internalizing receptor, and a nanoparticle surface-modified with a ligand that binds to the non-internalizing receptor.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: March 1, 2022
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MITN1)
    Inventors: Darrell J. Irvine, Yiran Zheng, Li Tang
  • Patent number: 11254748
    Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: February 22, 2022
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Patent number: 11254987
    Abstract: This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 22, 2022
    Assignee: GENENTECH, INC.
    Inventors: Edward Kadel, Marcin Kowanetz, Kimberly Walter
  • Patent number: 11255859
    Abstract: The present application relates to use of hexokinase-2 and a kit for detecting rare tumor cells in body fluid sample. The present application, based on a principle of abnormal tumor cell energy metabolism, conducts a vitro detection by using a glycolysis marker hexokinase-2 (HK2) as a marker, and assists localization and selection of the rare tumor cells by an addressable microporous array chip or a glass sheet, so as to implement a detection on rare tumor cells having high glycolysis activity in a cancer patient's body fluid sample.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 22, 2022
    Assignee: SUZHOU JUNHUI BIOTECHNOLOGY CO., LTD.
    Inventors: Liu Yang, Yingqi Hua, Zhengdong Cai
  • Patent number: 11254747
    Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through nonpeptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody like functionality to engineered into the molecule.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: February 22, 2022
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Patent number: 11248058
    Abstract: Provided herein are chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., CD19, CD30, GD2, etc.), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, 4-1BB, etc.). In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 15, 2022
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: Lung-Ji Chang
  • Patent number: 11214617
    Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: January 4, 2022
    Assignee: MabQuest SA
    Inventors: Giuseppe Pantaleo, Craig Fenwick
  • Patent number: 11213578
    Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: January 4, 2022
    Assignee: Treos Bio Limited
    Inventors: Julianna Lisziewicz, Levente Molnár, Enikő R. Tőke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
  • Patent number: 11207350
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: December 28, 2021
    Assignee: ImmunityBio, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Patent number: 11203640
    Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: December 21, 2021
    Assignees: Eli Lilly and Company, Zymeworks Inc.
    Inventors: Michael Dewain Kalos, Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Igor Edmondo Paolo D'Angelo, Gregory D Plowman